epilepsyintractable epilepsydrug-resistant epilepsyfocal epilepsyfocal epileptic seizuresantiepileptic drugbrivaracetamefficacytolerabilityэпилепсиятруднокурабельная эпилепсияфармакорезистентная эпилепсияфокальная эпилепсияфокальные эпилептические приступыантиэпилептический препаратбриварацетамэффективностьпереносимость1.Karlov V.A., Vlasov P.N., Zhidkova I.A. et al. Brivaracetam in the treatment of epilepsy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2017;117(9):55–62. (In Russ.).Карлов В.А., Власов П.Н., Жидкова И.А. и др. Бриварацетам в лечении больных эпилепсией. Журнал неврологии и психиатрии им. С.С. Корсакова 2017;117(9):55–62.2.Medication package insert for Briviact®. Available at: http://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=b8cf75da-e6454d3d-aa29-a64a9e35cd6f&t. (In Russ.).Инструкция по применению препарата Бривиак®. Доступно по: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b8cf75da-e645-4d3daa29-a64a9e35cd6f&t. .3.Andres E., Kerling F., Hamer H., Winterholler M. Behavioural changes in patients with intellectual disability treated with brivaracetam. Acta Neurol Scand 2018;138(3):195–202. PMID: 29658982. DOI: 10.1111/ane.12943.4.Ben-Menachem E., Mameniškienė R., Quarato P.P. et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology 2016;87(3):314–23. PMID: 27335114. DOI: 10.1212/WNL.0000000000002864.5.Biton V., Berkovic S.F., Abou-Khalil B. et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 2014;55(1):57–66. PMID: 24446953. DOI: 10.1111/epi.12433.6.Brodie M.J., Fakhoury T., McDonough B. et al. Brivaracetam-induced elevation of carbamazepine epoxide levels: A posthoc analysis from the clinical development program. Epilepsy Res 2018;145:55–62. DOI: 10.1016/j.eplepsyres.2018.06.002.7.Diaz A., Elmoufti S., Schiemann J., Whitesides J. Efficacy and safety of adjunctive brivaracetam for partial-onset (focal) seizures (POS) in patients with Type IC seizures at baseline: Pooled results from three fixed-dose, randomized, doubleblind, placebo-controlled, phase III studies. Neurology 2016;86(16 Suppl). Annual meeting of the 68th American Academy of Neurology (AAN), April 15–21, 2016, Vancouver, Canada. Abstr. P2.042.8.French J.A., Costantini C., Brodsky A. et al. Adjunctive Brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology 2010;75(6):519–25. DOI: 10.1212/ WNL.0b013e3181ec7f7f.French J.A., Costantini C., Brodsky A. et al. Adjunctive Brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology 2010;75(6):519–25. DOI: 10.1212/WNL.0b013e3181ec7f7f.9.Hirsch M., Hintz M., Specht A., SchulzeBonhage A. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: a monocenter retrospective outcome analysis. Seizure 2018;61:98–103. PMID: 30118932. DOI: 10.1016/j.seizure.2018.07.017.10.Klein P., Schiemann J., Sperling M.R. et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive Brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia 2015;56(12):1890–8. PMID: 26471380. DOI: 10.1111/ epi.13212.Klein P., Schiemann J., Sperling M.R. et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive Brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia 2015;56(12):1890–8. PMID: 26471380. DOI: 10.1111/epi.13212.11.Klein P., Diaz A., Gasalla T., Whitesides J. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol 2018;10:1–22. PMID: 29403319. DOI: 10.2147/CPAA.S114072.12.Kwan P., Trinka E., van Paesschen W. et al. Adjunctive Brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 2014;55(1):38–46. PMID: 24116853. DOI: 10.1111/ epi.12391.Kwan P., Trinka E., van Paesschen W. et al. Adjunctive Brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 2014;55(1):38–46. PMID: 24116853. DOI: 10.1111/epi.12391.13.Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9(7):464–8. PMID: 11034869. DOI: 10.1053/seiz.2000.0442.14.Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006;6(3):397–406. PMID: 16533143. DOI: 10.1586/14737175.6.3.397.15.Ryvlin P., Werhahn K.J., Blaszczyk B. et al. Adjunctive Brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia 2014;55(1):47–56. PMID: 24256083. DOI: 10.1111/epi.12432.16.Sanon N.T., Gagné J., Wolf D.C. et al. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model. Epilepsy Behav 2018;79:117–25. PMID: 29287214. DOI: 10.1016/j.yebeh.2017.11.019.17.Shoenmarker N., Wade J.R., Stockis A. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. Eur J Clin Pharmacol 2017;73(6):727–33. PMID: 28280887. DOI: 10.1007/s00228-017-2230-6.18.Stephen L.J., Brodie M.J. Brivaracetam: a novel antiepileptic drug for focal-onset seizures. Ther Adv Neurol Disord 2017;11:1756285617742081. PMID: 29399049. DOI: 10.1177/1756285617742081.19.Strzelczyk A., Steinig I., Klein K.M. et al. Brivaracetam for add-on treatment in focal epilepsy. Nervenarzt 2016;87(10):1086–93. PMID: 27389600. DOI: 10.1007/s00115016-0163-4.20.Strzelczyk A., Kay L., Bauer S. et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia 2018;59(8):1549–56. PMID: 29943451. DOI: 10.1111/ epi.14476.Strzelczyk A., Kay L., Bauer S. et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia 2018;59(8):1549–56. PMID: 29943451. DOI: 10.1111/epi.14476.21.Strzelczyk A., Klein K.M., Willems L.M. et al. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol 2016;9(5):637–45. PMID: 26891946. DOI: 10.1586/17512433.2016.1156529.22.Toledo M., Whitesides J., Schiemann J. et al. Safety, tolerability, and seizure control during long-term treatment with adjunctive Brivaracetam for partial-onset seizures. Epilepsia 2016;57(7):1139–51. PMID: 27265725. DOI: 10.1111/epi.13416.23.Van Paesschen W., Hirsch E., Johnson M. et al. Efficacy and tolerability of adjunctive Brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 2013;54(1):89–97. PMID: 22813235. DOI: 10.1111/j.1528-1167.2012.03598.x.24.Willems L.M., Bertsche A., Bösebeck F. et al. Retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany. Front Neurol 201823;9:569. PMID: 30083127. DOI: 10.3389/fneur.2018.00569.25.Wood M.D., Sands Z.A., Vandenplas C., Gillard M. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia 2018;59(9):e147–51. PMID: 30144048. DOI: 10.1111/ epi.14532.Wood M.D., Sands Z.A., Vandenplas C., Gillard M. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia 2018;59(9):e147–51. PMID: 30144048. DOI: 10.1111/epi.14532.26.Xiao X., Ouyang Y., Song Z., Zheng W. Progress in synaptic mechanism in epileptogenesis. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2018;43(1):90–4. PMID: 30154297. DOI: 10.11817/j. issn.1672-7347.2018.01.014.Xiao X., Ouyang Y., Song Z., Zheng W. Progress in synaptic mechanism in epileptogenesis. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2018;43(1):90–4. PMID: 30154297. DOI: 10.11817/j.issn.1672-7347.2018.01.014.27.Zahnert F., Krause K., Immisch I. et al. Brivaracetam in the treatment of patients with epilepsy-first clinical experiences. Front Neurol 2018;6;9:38. PMID: 29467714. DOI: 10.3389/ fneur.2018.00038.Zahnert F., Krause K., Immisch I. et al. Brivaracetam in the treatment of patients with epilepsy-first clinical experiences. Front Neurol 2018;6;9:38. PMID: 29467714. DOI: 10.3389/fneur.2018.00038.